Neoantigen vaccine for ovarian cancer that didn't fully respond
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a personalized vaccine made from your own immune cells and tumor mutations. It's for people with HRD-negative ovarian cancer who still have signs of cancer after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70 and weigh at least 99 pounds.
- You have had surgery and platinum chemo for ovarian cancer, but still have high CA125 levels or a tumor that can be seen on a scan.
- You are willing to have some of your blood cells collected to make a personalized vaccine.
- Your blood cell and organ function levels must be within certain safe ranges.
- You are not pregnant and agree to use effective birth control during the trial and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine (NeoOVSV) made from your tumor’s unique markers (neoantigens). It’s for women with Stage II or III epithelial ovarian cancer who had successful surgery to remove all visible cancer. The goal is to see if the vaccine is safe and helps your immune system fight any remaining cancer cells.
This trial tests a personalized vaccine for people with epithelial ovarian cancer who still have a small amount of cancer DNA in their blood after surgery. The goal is to see if the vaccine can help stop the cancer from coming back.
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
This study tests a personalized mRNA vaccine (NeoOVIV) for ovarian cancer patients who have already had surgery. The vaccine is designed to train your immune system to attack cancer cells that remain after surgery, based on unique markers in your tumor.
This trial tests a personalized vaccine made from your tumor's unique proteins to help your immune system fight high-risk or advanced endometrial cancer. It is given along with your regular cancer treatments.
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
Hear when a new HRD-negative Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.